WHOOP CEO, Will Ahmed: 50B Hours of Health Data, a 4 Million Member Data Moat, & the FDA Fight

WHOOP members wear the device an average of 23.6 hours a day, generating just over 50 billion hours of continuous physiological data, which CEO Will Ahmed describes as one of the world’s largest health datasets. WHOOP expects to end the year with around 4 million members. Growth accelerated over time: the company took about 12 years to reach 1 million members, roughly 18 more months to reach 2 million, and about six months after that to reach 3 million. Ahmed presents the scale of the membership and accumulated data as a foundation for improving the product.

Founded in 2012, WHOOP launched to consumers in 2017 with a $500 one-time purchase, then moved to a $15–$30 monthly subscription in 2018–19. Ahmed says early buyers engaged strongly, but the initial price did not generate enough customer growth. The subscription model shifted the company’s focus toward ongoing engagement, behavior change, health improvement, and software updates. Ahmed says WHOOP does not sell member data: in his framing, membership is the product, rather than the data itself.

WHOOP combines sensor readings with member-uploaded blood tests, advanced lab results, medical records, and journal entries. More than half of members journal daily across over 100 behaviors and lifestyle factors, around 80% interact with WHOOP’s AI, and members open the app about eight times a day. The company is building its own foundational models while also using open-source models. Ahmed sees the AI coach as a major part of WHOOP’s future, with the broader aim of turning continuous data into useful guidance rather than simply collecting readings.

WHOOP uses heart-rate variability, the variation in time between successive heartbeats, to assess stress and recovery against each person’s baseline; Ahmed says longer-term trends can also point to health changes. He described a fit baseball player whose sleeping heart rate rose from about 50 to 120–130 beats per minute before tests found stage-four Hodgkin lymphoma. In another case, a long-time member’s HRV fell from about 100 to 50 before testicular cancer was found; Ahmed said he did not believe low HRV was previously known as a lead indicator for that cancer. These anecdotes illustrate possible signals, not proof that WHOOP can diagnose cancer.

Ahmed says physiological signals might eventually indicate that a biomarker such as cortisol is out of range and prompt a targeted test, but he described such a signal as an indication rather than a confirmed diagnosis. WHOOP’s main product pillars are sleep, recovery, and strain. The company has added features including ECG monitoring, AFib detection, advanced labs, Healthspan, and blood-pressure insights through software and membership updates, while reserving new hardware for meaningful innovations. WHOOP users’ data also associates eating within three hours of bedtime with worse sleep and recovery, but Ahmed cautions that these behavioral insights show association, not causation.

For its blood-pressure algorithm, WHOOP enrolled 70,000 members in a study of stress, sleep, and blood pressure; participants uploaded readings daily for several weeks, and the company combined those readings with existing physiological data. Ahmed says WHOOP launched blood-pressure insights as a wellness feature, but the FDA said the feature required regulation and sent the company a warning letter. He says the FDA later updated its guidance to recognize wellness applications for blood-pressure measurement, and WHOOP’s insights remain available. Ahmed believes WHOOP’s case contributed to that change alongside feedback from across the industry; he did not claim it was the sole cause.

WHOOP’s ECG feature is FDA-cleared through a 510(k) process, Ahmed says, while the blood-pressure feature is a distinct wellness application. WHOOP supports cuff calibration before cuffless blood-pressure measurements. Ahmed says the company chose not to build its own cuffs because the technology seemed commoditized, with the longer-term aim of replacing the cuff. His stated goal is to measure difficult physiological signals with accuracy comparable to a medical device and make them available to consumers.